Needham & Company upgraded ResMed (NYSE: RMD) from Underperform to Hold.Analyst Mike Matson commented, "RMD's revenue and EPS both significantly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE